PSYBF (PsyBio Therapeutics) EV-to-OCF: 0.00 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics EV-to-OCF?

PsyBio Therapeutics PSYBF -90.00% EV-to-OCF is 0.00 as of Aug. 29, 2026.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PsyBio Therapeutics's Enterprise Value is $0.00 Mil. PsyBio Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.89 Mil. Therefore, PsyBio Therapeutics's EV-to-OCF for today is 0.00.

The historical rank and industry rank for PsyBio Therapeutics's EV-to-OCF or its related term are showing as below:

PSYBF's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.715
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-29), PsyBio Therapeutics's stock price is $1.0E-5. PsyBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.030. Therefore, PsyBio Therapeutics's PE Ratio (TTM) for today is At Loss.

PsyBio Therapeutics  (OTCPK:PSYBF) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PsyBio Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.0E-5/-0.030
=At Loss

PsyBio Therapeutics's share price for today is $1.0E-5.
PsyBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

PsyBio Therapeutics EV-to-OCF Related Terms

PsyBio Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics EV-to-OCF Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
EV-to-OCF
-2.05 -0.89

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PSYBF vs VRTX, REGN, SGEN: EV-to-OCF Comparison

For the Biotechnology subindustry, PsyBio Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyBio Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's EV-to-OCF falls into.


PsyBio Therapeutics EV-to-OCF Calculation

PsyBio Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.000/-0.889
=0.00

PsyBio Therapeutics's current Enterprise Value is $0.00 Mil.
PsyBio Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of 0.00 mean?
PsyBio Therapeutics (PSYBF) has a EV-to-OCF of 0.00 as of Aug. 29, 2026.
Is PsyBio Therapeutics' EV-to-OCF too high?
PsyBio Therapeutics' current EV-to-OCF is 0.00.
How does PsyBio Therapeutics' EV-to-OCF compare to VRTX and REGN?
PsyBio Therapeutics' EV-to-OCF of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. PsyBio Therapeutics's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (PSYBF) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PsyBio Therapeutics (PSYBF), the current EV-to-OCF is 0.00 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.